InfuSystem Holdings, Inc

InfuSystem Holdings, Inc. announced it will disclose its financial results for the second quarter of 2026 on Tuesday, August 4, 2026, before the market opens. The company will also host a conference call for investors on the same day at 9:00 a.m. Eastern Time to discuss these results. Details for participating in the call and accessing the webcast replay were provided.

InfuSystem Holdings, Inc. announced that its Board of Directors approved a new stock repurchase program, authorizing the company to buy back up to $20 million of its outstanding common stock. This program will commence on July 1, 2026, and run through June 30, 2028, superseding the previous authorization. CEO Carrie Lachance stated that the program reflects confidence in the company's ability to deliver profitable growth and drive long-term shareholder value, leveraging a strong balance sheet and cash flows.

Following its 2026 Annual Meeting of Stockholders, InfuSystem Holdings, Inc. announced the election of Beverly Huss as the new Chairman of the Board of Directors. Ms. Huss's appointment was made by the newly constituted Board on May 11, 2026. The company noted there are no special arrangements or family relationships related to her appointment, nor any material interests requiring disclosure.

InfuSystem Holdings, Inc. stockholders approved the Third Amendment to the 2021 Equity Incentive Plan, increasing the maximum number of shares reserved for issuance to 7,000,000. Additionally, all seven Board nominees were elected, and the compensation of named executive officers was approved on an advisory basis. Grant Thornton LLP was also ratified as the independent accounting firm for fiscal year 2026.

InfuSystem Holdings, Inc. reported a significant improvement in its first-quarter 2026 financial results, turning a net loss into a profit. Net income reached $1.02 million, or $0.05 per diluted share, compared to a net loss of $0.27 million in the prior year. Gross profit increased to $19.68 million, while net revenues saw a slight decrease to $33.68 million. The company also continued its share repurchase program, buying back $11.8 million in stock.

InfuSystem Holdings, Inc. reported first-quarter 2026 financial results, achieving a net income of $1.0 million, a significant improvement from a net loss of $0.3 million in the prior year. Net revenues decreased 3% to $33.7 million, primarily due to a strategic restructuring of a biomedical services contract, which management states improved overall profitability. Adjusted EBITDA remained flat at $6.4 million, with an expanded margin of 18.9%. The company reaffirmed its full-year 2026 guidance, anticipating pro-forma net revenue growth of 6% to 8%.

InfuSystem Holdings, Inc. announced that it will disclose its financial results for the first quarter of 2026 on Thursday, May 7, 2026, before the market opens. The company will also host a conference call for investors on the same day at 9:00 a.m. Eastern Time to discuss the results. Details for accessing the call and webcast replay were provided.